| Not Yet Recruiting | Home Monitoring in eAMD Treatment NCT07340372 | Association for Innovation and Biomedical Research on Light and Image | — |
| Not Yet Recruiting | Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Ref NCT07423429 | Nantes University Hospital | — |
| Not Yet Recruiting | An Assistant Model for Anti-VEGF Therapy Decision NCT07328776 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Recruiting | Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macul NCT07235527 | Saglik Bilimleri Universitesi | — |
| Not Yet Recruiting | Ethical Issues of Using Gene Therapy in the Treatment of AMD NCT07004361 | Nantes University Hospital | — |
| Withdrawn | Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy NCT04075136 | Wake Forest University Health Sciences | Phase 4 |
| Completed | A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injec NCT04640272 | Ribomic USA Inc | Phase 2 |
| Completed | Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph NCT04723160 | Visionary Intelligence Ltd. | — |
| Completed | A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneratio NCT04200248 | Ribomic USA Inc | Phase 2 |
| Unknown | Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD NCT05539235 | First Affiliated Hospital of Chongqing Medical University | Phase 2 / Phase 3 |
| Completed | Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti- NCT03071055 | Southeast Clinical Research Associates, LLC | Phase 2 |
| Completed | Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizum NCT04138420 | Federico II University | — |
| Unknown | Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy NCT02976194 | Pusan National University Hospital | Phase 4 |
| Completed | Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD NCT02732899 | Maturi, Raj K., M.D., P.C. | Phase 2 |
| Completed | Intravitreal Aflibercept for Submacular Hemorrhage NCT03169660 | Kim's Eye Hospital | Phase 4 |
| Completed | Stem Cell Therapy for Outer Retinal Degenerations NCT02903576 | Federal University of São Paulo | Phase 1 / Phase 2 |
| Terminated | X-82 to Treat Age-related Macular Degeneration NCT02348359 | Tyrogenex | Phase 2 |
| Completed | LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration NCT02355028 | Alcon, a Novartis Company | Phase 2 |
| Completed | Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD NCT03744806 | Medical University of Lublin | — |
| Unknown | Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degen NCT02328209 | Mie University | N/A |
| Completed | Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept NCT02125864 | Oslo University Hospital | Phase 4 |
| Unknown | Monocentric Retrospective Observational Study on Patients With Macular Degeneration NCT02089503 | Hospital St. Joseph, Marseille, France | — |
| Unknown | Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910 NCT01961414 | Palmetto Retina Center, LLC | Phase 4 |
| Completed | Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy NCT01950741 | Pusan National University Hospital | Phase 4 |
| Completed | ESBA1008 Microvolume Study NCT01849692 | Alcon Research | Phase 2 |
| Completed | Efficacy and Safety Study of ESBA1008 Versus EYLEA® NCT01796964 | Alcon Research | Phase 2 |
| Completed | Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD NCT01414153 | Lpath, Inc. | Phase 2 |
| Completed | Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Relat NCT01526070 | Stanford University | — |
| Completed | Addition of 20mg/Day Zeaxanthin to Triple Therapy Treatment Options for Age Related Macular Degeneration (ARMD NCT01527435 | The Retina Center of St. Louis County, PC | — |
| Unknown | Long-term Follow-up of Subfoveal Neovascular AMD NCT01608113 | Medical University of Vienna | — |
| Completed | Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zea NCT01404845 | Affordance | N/A |
| Completed | Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration NCT01157065 | Alcon Research | Phase 2 |
| Completed | Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD NCT01819415 | Maisonneuve-Rosemont Hospital | N/A |
| Completed | FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degenerati NCT01500915 | Institut de la Macula y la Retina | Phase 4 |
| Completed | ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients NCT01304693 | Alcon Research | Phase 1 / Phase 2 |
| Completed | Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab NCT01810042 | Pusan National University Hospital | Phase 4 |
| Completed | ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration NCT01213082 | University of California, Davis | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion NCT00913744 | ThromboGenics | Phase 2 |
| Completed | The Spectralis-Cirrus Study NCT00927303 | The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | — |
| Completed | LUCAS (Lucentis Compared to Avastin Study) NCT01127360 | Oslo University Hospital | Phase 4 |
| Completed | A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherap NCT00793923 | Subhransu K. Ray, M.D., Ph.D. | Phase 1 / Phase 2 |
| Completed | Bevacizumab for Neovascular Age-related Macular Degeneration NCT01306591 | Peking University People's Hospital | N/A |